Table 5.
Multivariable Logistic Regression Analysis to Compare Treatment Effectiveness in Molnupiravir and Nirmatrelvir/Ritonavir Recipients
| Explanatory Variable | Odds Ratio | 95% CI | P Value |
|---|---|---|---|
| Model 1a | |||
| Treatment | |||
| Molnupiravir recipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.58 | .46–.75 | <.001 |
| Age, per year | 1.05 | 1.03–1.06 | <.001 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.25 | .09–.56 | .003 |
| Vaccination status | |||
| Nonvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.32 | .25–.43 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.43 | .32–.59 | <.001 |
| Comorbiditiesb | |||
| None | 1.00 | … | … |
| 1 | 1.15 | .85–1.56 | .37 |
| 2 | 1.56 | 1.12–2.17 | .008 |
| 3 | 2.05 | 1.30–3.18 | .002 |
| >3 | 2.56 | .97–5.65 | .03 |
| Model 2c | |||
| Treatment | |||
| Molnupiravir recipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.69 | .46–1.06 | .09 |
| Age, per year | 1.11 | 1.09–1.14 | <.001 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.30 | .48–1.02 | .10 |
| Vaccination status | |||
| Nonvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.29 | .19–.46 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.22 | .12–.40 | <.001 |
| Comorbidities | |||
| None | 1.00 | … | … |
| 1 | 0.70 | .44–1.14 | .14 |
| 2 | 0.85 | .49–1.48 | .57 |
| 3 | 1.08 | .43–2.38 | .86 |
| >3 | 4.82 | 1.58–12.04 | .002 |
| Model 3d | |||
| Treatment | |||
| Molnupiravir recipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.30 | .16–.56 | <.001 |
| Previous iCOVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.50 | .08–1.91 | .38 |
| Vaccination status | |||
| Nonvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.32 | .16–.67 | .001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.45 | .19–1.09 | .07 |
| Model 4e | |||
| Treatment | |||
| Molnupiravir recipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.56 | .32–.98 | .04 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.29 | .02–1.51 | .24 |
| Vaccination status | |||
| Nonvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.45 | .23–.93 | .02 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.54 | .26–1.21 | .12 |
| Model 5f | |||
| Treatment | |||
| Molnupiravir recipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.67 | .40–1.16 | .15 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 1.20 | .32–3.64 | .76 |
| Vaccination status | |||
| Nonvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.44 | .23–.91 | .02 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.34 | .16–.76 | .007 |
| Model 6g | |||
| Treatment | |||
| Molnupiravir recipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.69 | .50–.97 | .03 |
| Vaccination status | |||
| Nonvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.29 | .21–.97 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.42 | .28–.64 | <.001 |
| Comorbidities | |||
| None | 1.00 | … | … |
| 1 | 1.27 | .87–1.91 | .22 |
| 2 | 1.52 | .99–2.36 | .06 |
| 3 | 1.98 | 1.06–3.56 | .03 |
| >3 | 2.05 | .48–5.97 | .25 |
Abbreviations: BMI, body mass index; ICU, intensive care unit.
Model 1: hospitalization without ICU admission, clinical deterioration, or death vs no hospitalization, ICU admission, clinical deterioration, or death.
Comorbidities include obesity (BMI ≥35 kg/m2), cardiovascular disease, T2DM, chronic liver disease, chronic kidney disease, and chronic lung disease. Individuals diagnosed with moderate to severe immunosuppression were excluded.
Model 2: death with or without ICU admission or clinical deterioration vs no hospitalization, ICU admission, clinical deterioration, or death.
Model 3: hospitalization without ICU admission, clinical deterioration, or death vs no hospitalization, ICU admission, clinical deterioration, or death among those 65 to 69 years of age.
Model 4: hospitalization without ICU admission, clinical deterioration, or death vs no hospitalization, ICU admission, clinical deterioration, or death among those 70 to 74 years of age.
Model 5: hospitalization without ICU admission, clinical deterioration, or death vs no hospitalization, ICU admission, clinical deterioration, or death among those 75 to 79 years of age.
Model 6: hospitalization without ICU admission, clinical deterioration, or death versus no hospitalization, ICU admission, clinical deterioration, or death among those ≥80 y of age.